Search
Cyclophosphamide Treatment Options
A collection of 2169 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
589 - 600 of 2169
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
Active Not Recruiting
This phase II trial studies the side effects and how well giving paclitaxel and cyclophosphamide with or without trastuzumab before surgery works in treating patients with previously untreated breast cancer. Drugs used in chemotherapy, such as paclitaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, may block tumor growth in different ways by targeting cert... Read More
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
11/22/2024
Locations: Nebraska Medicine-Bellevue, Bellevue, Nebraska +3 locations
Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
A Phase 1/2 Trial of ADI-270 in CcRCC
Recruiting
This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee
Conditions: Clear Cell Renal Cell Carcinoma
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Active Not Recruiting
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
Gender:
ALL
Ages:
Between 3 years and 25 years
Trial Updated:
11/18/2024
Locations: Children's Hospital of Alabama ( Site 0023), Birmingham, Alabama +92 locations
Conditions: Hodgkin Lymphoma
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Not Yet Recruiting
This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL).
The name of the study drugs involved in this study are:
* Tazemetostat (a type of inhibitor for Enhancer of Zeste Homolog 2 (EZH2))
* Standard of care CHOP therapy:
* Cyclophosphamide (a type of alkylating agent)
* Doxorubicin (a type of anthracycline antibiotic)
* Vincristine (a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Terminated
The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine \[R-B\] and rituximab in combination with a 4 drug combination of cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone \[R-CHOP\]) is effective and safe, compared with placebo in combination with standard immunochemotherapy (R-B or R-CHOP) in patients with relapsed iNHL who have received at least one, but at most three, lines of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Ironwood Physicians P.C. DBA Ironwood Cancer & Res. Ctr., Chandler, Arizona +200 locations
Conditions: Lymphoma, Non-Hodgkin
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
Active Not Recruiting
This phase II trial will examine whether genetically reprogramming a patient's disease fighting white blood cells may build an immune response to kill cancer cells that express the NY-ESO-1 protein. In this study, this genetic therapy will be given during a stem cell transplant along with a vaccine therapy. The vaccine will be made using the NY-ESO-1 protein and may help to stimulate the engineered immune response to tumor cells.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
11/14/2024
Locations: University of California at Los Angeles (UCLA ), Los Angeles, California
Conditions: Malignant Neoplasm
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
Completed
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
After the end of KTE-C19-112 (ZUMA-12), participants who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15-year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Banner Health MD Anderson Cancer Center, Gilbert, Arizona +6 locations
Conditions: B-cell Lymphoma
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
Recruiting
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/11/2024
Locations: Aflac Cancer & Blood Disorders Centers, Atlanta, Georgia +4 locations
Conditions: Solid Tumor
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
Completed
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/11/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Hematologic Malignancy
Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
Recruiting
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama +14 locations
Conditions: Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Active Not Recruiting
The purpose of this study is to find out what effects, good and/or bad, the combination of irinotecan and temozolomide has on Ewing sarcoma.
Irinotecan and temozolomide are chemotherapy drugs that are used very often to treat pediatric patients at MSKCC. The investigators have used these two drugs for many years to treat patients with Ewing sarcoma whose cancer has relapsed.
For patients with newly diagnosed Ewing sarcoma the current standard of care at MSKCC is a five drug chemotherapy regime... Read More
Gender:
ALL
Ages:
Between 1 year and 40 years
Trial Updated:
11/11/2024
Locations: Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Newly Diagnosed Ewing Sarcoma
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Terminated
The primary purpose of this sub study is to assess the safety, tolerability and determine recommended Phase 2 dose (RP2D) of GSK3901961 in HLA A\*02:01, HLA-A\*02:05 and/or HLA A\*02:06 positive participants with New York esophageal squamous cell carcinoma (NY ESO 1) and/or Cancer testis antigen 2 (LAGE 1a) positive previously treated metastatic Non-Small Cell Lung Cancer (NSCLC) and previously treated, advanced (metastatic or unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma SS/MRCL... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: GSK Investigational Site, New Haven, Connecticut +20 locations
Conditions: Neoplasms
589 - 600 of 2169